Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 1019-1027

  Van der Burg, Sjoerd H ^a   Menon, Anand G ^b   Redeker, Anke ^a   Bonnet, Marie Claude ^c   Drijfhout, Jan Wouter ^a   Tollenaar, Rob A E M ^b   Van de Velde, Cornelis J H ^b   Moingeon, Philippe ^c   Kuppen, Peter J K ^b   Offringa, Rienk ^a   Melief, Cornelis J M ^a  

^a Department of Immunohematology and Blood Transfusion ^*  (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 4; PROTEIN P53; RECOMBINANT ALVAC P53 VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MALE; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; SERUM; T LYMPHOCYTE; VACCINATION;

ADULT; AGED; ANTIBODY FORMATION; CANARYPOX VIRUS; CANCER VACCINES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VACCINATION;

EID: 0036093592     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Phase I clinical trial of a recombinant canarypox-virus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule
2. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen
3. Specific cytolytic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
4. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies
5. Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma
6. Strategies for immunotherapy of cancer
7. p53 as a target for cancer vaccines: Recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge
8. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
9. p53 in colorectal cancer: Clinicopathological correlation and prognostic significance
10. p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance
11. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis
12. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
13. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
14. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas
15. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
16. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses
17. p53: A potential target antigen for immunotherapy of cancer
18. Antibodies against p53 are associated with poor prognosis of colorectal cancer
19. Serum p53 antibodies as early markers of lung cancer
20. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status
21. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases
22. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma
23. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer
24. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
25. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells
26. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p53 65-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein
27. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms
28. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer
29. Long lasting p53-specific T cell memory responses in the absence of anti-p53 anti-bodies in patients with resected primary colorectal cancer
30. Applications of pox virus vectors to vaccination: An update
31. Recombinant viruses as a tool for therapeutic vaccination against human cancers
32. The safety and use of canarypox vectored vaccines
33. Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53
34. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity
35. Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques
36. Natural T-helper immunity against human papilloma-virus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: Identification of 3 human leukocyte antigen class II-restricted epitopes
37. A multiparametric observation of immune competence in breast cancer and its correlation with tumour load and prognosis
38. p53 antibodies in the sera of patients with various types of cancer: A review
39. Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma
40. CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice
41. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
42. Importance of CD4(+) T helper cell responses in tumor immunity
43. The central role of CD4(+) T cells in the antitumor immune response
44. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
45. CD4+ helper T cells are required for resistance to a highly metastatic murine tumor
46. Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers
47. Eradication of adenovirus E1-induced tumors by EA-specific cytotoxic T lymphocytes
48. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
49. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
50. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
51. High-level IL-12 production by human dendritic cells requires two signals
52. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines